PBAC's latest decision on Vorasidenib: Recommended with restriction (2025). Considered for Treatment of patients with WHO Grade 2 IDH-mutant astrocytoma or oligodendroglioma who have residual or recurrent disease after at least one prior surgery and are not in immediate need of radiotherapy or chemotherapy.
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
—
ICER not stated
Submissions
1
first 2025
Submissions
1
2025 → 2025
Eligible population
Adults with WHO Grade 2 IDH-mutant astrocytoma or oligodendroglioma (IDH1 R132H/C/G/S/L or IDH2 R172K/M/W/S/G variants) with residual or recurrent disease after at least one prior surgery, ECOG performance status ≤1, not in immediate need of radiotherapy/chemotherapy, and without prior systemic anticancer therapy or radiotherapy.
Therapy area
Oncology
Line of therapy
First-line
Evidence base
RCT
Primary endpoint
PFS
Key trials
INDIGO
Comparator
active surveillance
Economic model
CEA
ICER note
ICER values not stated in the provided text excerpt.